FDA
-
-
-
-
-
-
-
Compass Pathways reports 6-month data from second psilocybin Phase 3 trial
-
-
-
-
-
-
-
DATAcc by DiMe releases first set of digital measures built specifically for common mental health disorders
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Compass Pathways (CMPS)
-
-
-
-
-
-
-
Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
-
-
-
-
-
-
-
FDA advances psychedelic drug studies for mental health treatment
-
-
-
-
-
-
-
Compass Pathways launches grant program for COMP360 provider training
-
-
-
-
-
-
-
Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights
-
325,726 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

